Posaconazole
- Generic Name
- Posaconazole
- Brand Names
- Noxafil, Posanol, Posaconazole Accord, Posaconazole AHCL
- Drug Type
- Small Molecule
- Chemical Formula
- C37H42F2N8O4
- CAS Number
- 171228-49-2
- Unique Ingredient Identifier
- 6TK1G07BHZ
- Background
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
- Indication
For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with...
- Associated Conditions
- Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Invasive bronchopulmonary aspergillosis, Mucormycosis, Oropharyngeal Candidiasis, Prophylaxis of Aspergillus infection, Pulmonary cryptococcosis infection
- Associated Therapies
- -
Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06541067
- Locations
- 🇫🇷
CHU Nantes, Nantes, France
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 249
- Registration Number
- NCT05065658
- Locations
- 🇮🇹
San Martino Polyclinic Hospital IRCCS, Genova, Italy
🇫🇷University of Rennes, Rennes, France
🇦🇹Medical University of Graz, Graz, Styria, Austria
A Study of BGB-11417 in Participants With Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 260
- Registration Number
- NCT04771130
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 600
- Registration Number
- NCT04368559
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇧🇪University Hospitals Leuven, Campus Gasthuisberg - UZ Leuven, Leuven, Belgium
🇫🇷Grenoble Alpes University Hospital Center, Grenoble, France
PTX3-targeted Antifungal Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Bochud Pierre-Yves
- Target Recruit Count
- 320
- Registration Number
- NCT03828773
- Locations
- 🇫🇷
Henri Mondor Hospital, Créteil, Ile De France, France
🇧🇪University Hospital Leuven (UZ Leuven), Leuven, Belgium
🇧🇪AZ Sint-Jan Hospital, Bruges, Belgium
Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 120
- Registration Number
- NCT03796533
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Hematology department, Pierre-Bénite, France
HDM201 Added to CT in R/R or Newly Diagnosed AML
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03760445
Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 36
- Registration Number
- NCT03614455
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
Modified Release Posaconazole in Patients With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 20
- Registration Number
- NCT03421366
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.